Boulevard, Odense, Denmark The "incretin effect" denotes an enhanced pancreatic insulin secretion after oral compared with intravenous ingestion of similar glucose loads (1-3). The incretin effect is supposed to be mediated through release of one or more insulinotropic hormones from the gut after oral glucose ingestion (2, 3). Two gut incretin hormones have been identified: gastric inhibitory polypeptide (GIP) (4, 5) and glucagon-like peptide 1 (GLP-1) (6-8). Gastric inhibitory polypeptide is secreted in the proximal part and GLP-1 in the distal part of the small intestine in response to mixed meals, oral glucose and fat ingestion (4, 8 
The incremental glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) responses (areas under curves; AUCs) were determined during a standard 180-min 75-g oral glucose tolerance test in a group of 12 identical twin pairs discordant for non-insulin-dependent diabetes mellitus (NIDDM) and 13 matched controls without family history of diabetes using highly sensitive and specific radioimmunoassay hormone assays. Data were analysed using multifactor analysis of variance (ANOVA) to identify and correct for possible covariates and to correct for multiple comparisons. Fasting plasma GLP-1 and GIP concentrations were similar in all groups. The twins with frank NIDDM had a decreased incremental GLP-1 response during oral glucose ingestion compared with controls without family history of diabetes (AUC\m=+-\sem;0.55 \m=+-\0.14 vs 1.17 \ m=+-\0. 25 (mmol/l) \ m=x\min, p < 0.05). The incremental GLP-1 secretion in the non-diabetic twins was not significantly different from neither their NIDDM co-twins nor the controls without family history of diabetes. The incremental GIP responses were similar in all study groups. Gender was identified as the major independent covariate for incremental glucose, insulin, GIP Boulevard, Odense, DK-5000, Denmark
The "incretin effect" denotes an enhanced pancreatic insulin secretion after oral compared with intravenous ingestion of similar glucose loads (1) (2) (3) . The incretin effect is supposed to be mediated through release of one or more insulinotropic hormones from the gut after oral glucose ingestion (2, 3) . Two gut incretin hormones have been identified: gastric inhibitory polypeptide (GIP) (4, 5) and glucagon-like peptide 1 (GLP-1) (6) (7) (8) . Gastric inhibitory polypeptide is secreted in the proximal part and GLP-1 in the distal part of the small intestine in response to mixed meals, oral glucose and fat ingestion (4, 8) . Both GIP and GLP-1 stimulate the secretion of insulin in the pancreatic /3-cells (4, 8) (9) . Importantly, other studies have indicated a decreased incretin effect in NIDDM patients (10 Table 2 were analysed by means of a multifactor analysis of variance (ANOVA), (Table 2 ). The incremental insulin secretion (AUC) during the OGTTs was, as reported previously (9) , significantly decreased in the NIDDM twins compared with both their non-diabetic co-twins (NGTTs and IGTTs) and controls without a family history of diabetes (Table 2 and Fig. 1 ). The non-diabetic twins (NGTTs and/or IGTTs) and controls had similar incremental insulin AUCs during the OGTTs (Table 2 and Fig. 1 ). However, as also reported previously (9) . the (Fig. 1) (Table 2 and Fig. 1 ). The incremental GLP-1 response in the nondiabetic twins was not significantly different from their identical NIDDM co-twins and nor was it different from the control subjects without any family history of diabetes (Table 2 and Fig. 1 The study also demonstrated normal intestinal GIP secretion during oral glucose ingestion in the group of non-diabetic co-twins of the NIDDM twins. Therefore, a defective or delayed intestinal GIP secretion does not explain the delayed insulin secretion in the non-diabetic twins reported previously (9) .
Previous studies reported higher incremental insulin (22) (23) (24) and GIP responses (25, 
